Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody

Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody

US Patent 11267876 · Granted Mar 8, 2022

Estimated economic value: $2,930,000 ⓘ

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Use of beta-catenin as a biomarker for treating cancers using anti-Dkk-1 antibod2025
Use of beta-catenin as a biomarker for treating cancers using anti-Dkk-1 antibod2025
Treatment of conditions associated with hyperinsulinaemia2021
Bromodomain inhibitors2018